InTune Workspace - Wisconsin Territory

RELIVE Units

45 units

vs Goal: 48 units | QTD

↓ 7.8% vs goal

Market Share

21.6% #4 position

vs National: 25.3% | QTD

↓ 1.20pp vs prior quarter

RELIVE Safety Perception (ATU)

58 Q3 wave

vs Q2 wave: 68 | Delta: -10 pts

↓ 10 pts vs Q2

Call Activity

1.7 calls/day

vs Goal: 1.5 calls/day | QTD

↑ 12% vs prior quarter

How is my brand performing?

3 New Insights

Pinned Insight

Units vs Goals trending below target

Territory delivered 45 units against 48-unit goal, representing a -6.3% shortfall. Performance gap widened from -3% (prior quarter) to current -6.3%, indicating accelerating underperformance.

Source: Specialty Pharmacy (QTD) Jan 2026

Pinned Insight

Market share 2.7pp below national average

RELIVE market share declined from 22.8% to 21.6% (Q4 2024), while national average holds at 25.3%. Historical trend shows consistent 2.5-2.7pp gap persisting over past year.

Source: DDD (QTD) Jan 2026

Pushed Insight

RELIVE New Starts Declining in Wisconsin

Patient volume remains stable at 847-863, indicating this decline represents a conversion challenge rather than a patient availability issue. RELIVE declined from 48 to 46 over 8 weeks (-4.2%). Analysis identified three key neurologists driving this trend; primary barrier is safety profile concerns amplified by competitor messaging positioning better tolerability despite lower efficacy.

Source: IQVIA (QTD) Jan 2026

Which HCPs show performance concerns?

3 New Insights

What is my territory payer mix and access status?

3 New Insights

Pinned Insight

Commercial & HIX dominate at 46.6% combined

Commercial payer mix increased from 22.8% to 24.4% over past year (+1.6pp), while Medicare share declined from 17.2% to 15.6% (-1.6pp). HIX maintained stable 22.2%, creating favorable private payer concentration for premium pricing strategies.

Source: IQVIA Claims Data (QTD) Jan 2026

Pinned Insight

Only 22% unrestricted access - majority face barriers

Unrestricted access decreased from 24.1% to 22.2% over past 6 months (-1.9pp), while PA requirements grew from 13.8% to 15.6% (+1.8pp). Combined barrier rate (PA + Step + Not Covered) now affects 53.4% of territory patient base.

Source: IQVIA Access Data (C6M) Jan 2026

Pinned Insight

PA approval rates declining quarter-over-quarter

PA approval rate dropped from 73% (Q3 2024) to 67% (Q4 2024), with average processing time increasing from 5.8 to 12.3 days. Denial rate for therapy use specifically increased 34% vs prior quarter, directly correlating with new starts decline.

Source: IQVIA Access Data (C6M) Jan 2026

Which HCPs should I focus on, and why?

1 New Insight

Only 12 HCPs are Tier A, but 5 have had zero contact in 45+ days. Those 5 alone represent 847 patients and an estimated $2.1M at risk. Dr. Thompson (47 days, 156 patients) and Dr. Chen (62 days) are the highest-leverage re-engagement targets; one re-engaged Tier A typically unlocks 3–4x the ROI of a mid-tier call.

Source: Veeva CRM (QTD) Jan 2026

Show By Days since last call Filter By Values Competitor Select

Customer ID ↑	Customer Name	Tier	Address	City	State	Zip	SP+SD Volume (Curr)	SP+SD Volume (Prev)	Total Calls	Total INPR Calls	F2F Calls	Virtual Calls	Phone Calls	Others Calls	RTE Sent	Last Call Date	Last Call Mode	Priority	Barriers
CUST-00001	Dr. Karen Allen	Tier 1	101 Main St	Wisconsin	CA	95101	21	13	11	12	1	1	1	1	1	01/28/2026	Virtual	First	Coverage / reimbursement
CUST-00002	Dr. Michael Chen	Tier 3	102 Main St	Wisconsin	CA	95102	21	16	14	15	2	2	2	0	2	01/25/2026	Phone	Second	Competitive messaging
CUST-00007	Dr. Emily Roberts	Tier 2	107 Main St	Wisconsin	CA	95107	21	16	14	15	2	3	1	1	1	01/13/2026	Virtual	First	New indication awareness
CUST-00012	Dr. Daniel Brown	Tier 3	112 Main St	Wisconsin	CA	95112	21	16	14	15	2	0	0	0	0	12/28/2025	F2F	Second	Samples / dosing
CUST-00017	Dr. Rachel Green	Tier 1	117 Main St	Wisconsin	CA	95117	21	16	14	15	2	1	5	1	2	12/13/2025	Phone	First	Guideline updates
CUST-00022	Dr. Jason Miller	Tier 3	122 Main St	Wisconsin	CA	95122	21	16	14	15	2	2	4	0	1	11/28/2025	Virtual	Second	Reintroduce brand
CUST-00027	Dr. Christina Young	Tier 2	127 Main St	Wisconsin	CA	95127	21	16	14	15	2	3	3	1	0	11/13/2025	F2F	First	Competitive messaging
CUST-00032	Dr. Nathan Evans	Tier 3	132 Main St	Wisconsin	CA	95132	21	16	14	15	2	0	2	0	2	10/25/2025	Phone	Second	KOL event invite
CUST-00006	Dr. David Park	Tier 3	106 Main St	Wisconsin	CA	95106	18	13	11	12	1	2	0	0	0	01/15/2026	F2F	Second	Formulary / access
CUST-00011	Dr. Amanda Foster	Tier 2	111 Main St	Wisconsin	CA	95111	18	13	11	12	1	3	5	1	2	01/01/2026	Phone	First	Combination therapy data

RELIVE Units

Market Share

RELIVE Safety Perception (ATU)

Call Activity

How is my brand performing?

Units vs Goals trending below target

Market share 2.7pp below national average

RELIVE New Starts Declining in Wisconsin

Which HCPs show performance concerns?

Bottom 5 HCPs by declining

HCPs with no recent contact

Engagement quality erosion in Strategic Accounts

What is my territory payer mix and access status?

Commercial & HIX dominate at 46.6% combined

Only 22% unrestricted access - majority face barriers

PA approval rates declining quarter-over-quarter

Which HCPs should I focus on, and why?

RELIVE Units

Market Share

RELIVE Safety Perception (ATU)

Call Activity

How is my brand performing?

Units vs Goals trending below target

Market share 2.7pp below national average

RELIVE New Starts Declining in Wisconsin

Which HCPs show performance concerns?

Bottom 5 HCPs by declining

HCPs with no recent contact

Engagement quality erosion in Strategic Accounts

What is my territory payer mix and access status?

Commercial & HIX dominate at 46.6% combined

Only 22% unrestricted access - majority face barriers

PA approval rates declining quarter-over-quarter

Which HCPs should I focus on, and why?

Add to Collection